Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research    » Alternative Medicine    » Beta Cells    » Cause    » Cells    » Children    » Complications    » Control    » Cure    » Diagnosis    » Drugs    » Elderly    » Genes    » Immune Cells    » Inhaled Insulin    » Insulin    » Islet Cells    » Neuropathy    » Obesity    » Oral Insulin    » Other Diseases    » Pets    » Pre-Diabetes    » Prevention    » Research    » Retinopathy    » Risk Factors    » Stem Cells    » Technology    » Testing    » Transplants    » Treatments    » Trials    » Type 1    » Type 2 Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Research » Trials

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Early Treatment Doubles Chance of Success for People with Diabetes Posted: Sunday, March 21, 2010

Results from the first study that compares failure rates of Metformin in real-world setting are out.

Postprandial Hyperglycemia and Increased Cardiovascular Risk Posted: Sunday, March 21, 2010

Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in patients with Type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with Type 2 diabetes.

FDA Reviewers Urge Pulling Rosiglitazone Posted: Sunday, February 28, 2010

Two FDA reviewers have recommended that the diabetes drug rosiglitazone (Avandia) be pulled from the market because of its link to major cardiac events.

Effect of Periodontal Treatment on Glycemic Control of Diabetic Patients Posted: Sunday, February 21, 2010

There is growing evidence that periodontitis may affect general health. This study by university researchers from the Netherlands was assigned to explore the robustness of observations that periodontal therapy leads to the improvement of glycemic control in diabetic patients.

Vinegar Decreases Postprandial Hyperglycemia in Patients with Type 1 Posted: Sunday, February 21, 2010

Vinegar could be easily used as a complementary food (e.g., in a salad dressing) to reduce hyperglycemia.

Use of Metformin in Type 1's Posted: Sunday, February 14, 2010

Metformin reduces insulin-dose requirement in Type 1 diabetes. As adding metformin to insulin therapy has been advocated in Type 1 diabetes, researchers at the Universities of Dundee and Aberdeen, U.K., conducted a systematic review of published clinical trials and clinical trial databases to assess the effects on HbA1c, weight, insulin-dose requirement and adverse effects.

Preventing Diabetes for Ten Years Plus Posted: Sunday, February 14, 2010

Ten-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Artificial Pancreas Improves Glucose Control Posted: Sunday, February 14, 2010

Closed-loop insulin delivery systems can improve overnight blood sugar control and reduce hypoglycemia risk in young patients with Type 1 diabetes, researchers have found.

Caloric Restriction with or without Exercise: The Fitness versus Fatness Debate Posted: Sunday, February 14, 2010

There is a debate over the independent effects of aerobic fitness and body fatness on mortality and disease risks.

New GLP-1 Medication Lowers A1c Six Months after Treatment Stopped Posted: Sunday, February 07, 2010

Transition Therapeutics announces results of a Phase 2 study of TT-223 (GLP-1 Cpd + Gastrin) in Type 2 diabetes patients. The results show that beta-cells can possibly be generated and/or restored. After a 10 week trial the drug was stopped and 6 months later, the A1c had dropped by 1.13 points.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.